Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

2.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.4K
Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

1.7K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.7K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

319
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
319

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cuproptosis Inducers in Cancer Therapy: State of the Art and Challenges.

Chemical record (New York, N.Y.)·2026
Same author

Surface plasmon resonance as a breakthrough tool for characterizing the size and shape of graphene quantum dots.

Nanoscale·2026
Same author

Quantitative Measurement of Hexoses by Betaine Aldehyde Derivatisation.

International journal of molecular sciences·2026
Same author

Citicoline Triggers Proteome Remodeling and Proteostatic Adaptation: Evidence from Shotgun Proteomics.

Pharmaceutics·2026
Same author

The Interplay Between the Ubiquitin-Proteasome System and Oxidative Stress: A Future Perspective in Eye Diseases.

Antioxidants (Basel, Switzerland)·2025
Same author

Exploring the effect of copper on the bioactivity of 8-quinolines: an <i>in vitro</i> and <i>in vivo</i> study.

Dalton transactions (Cambridge, England : 2003)·2025
Same journal

Eco-Friendly Synthesis of <i>Cynara scolymus</i> Extract-Mediated Nickel Oxide Nanoparticles for Antibacterial and Catalytic Wastewater Applications: Experimental and Molecular Docking Evidence.

Bioinorganic chemistry and applications·2026
Same journal

Synthesis, Structural Characterization, and DFT Studies of Fe(III), Co(II), and Ni(II) Mixed-Ligand Complexes With Albendazole and Nifuroxazide With Molecular Docking Against Respiratory Pathogen Targets.

Bioinorganic chemistry and applications·2026
Same journal

Synthesis, Characterization, and Anticancer Activity of Vanadium (III) Complexes With Pyridyl-Triazole Ligands.

Bioinorganic chemistry and applications·2026
Same journal

Plant-Mediated Fabrication of Silver Nanoparticles Using <i>Elaeagnus angustifolia</i> Flowers: In Vitro Evaluation of Antibacterial, Antifungal, Antioxidant, and Toxic Effects and Biomolecular Interactions With ct-DNA and HSA.

Bioinorganic chemistry and applications·2026
Same journal

Synthesis, Characterization, Electrochemical Properties, and DNA-Binding Studies of Novel Schiff Base Metal Complexes: Catalysts in Transfer Hydrogenation of D-Glucose-Like Aldose Reductase Mimetics.

Bioinorganic chemistry and applications·2026
Same journal

Phytofabrication of Zinc Oxide Nanoparticles Using <i>Sida cordifolia</i> L. and Their Biomedical Applications.

Bioinorganic chemistry and applications·2026
See all related articles

Related Experiment Video

Updated: Mar 7, 2026

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
09:22

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

Published on: January 2, 2015

19.1K

Tolcapone Interferes With Key Pathological Features in Alzheimer's Disease.

Alessia Distefano1, Damiano Calcagno2, Giuseppe Grasso1

  • 1Università degli Studi di Catania, v.le A. Doria 6, Catania, 95125, Italy, unict.it.

Bioinorganic Chemistry and Applications
|March 6, 2026
PubMed
Summary
This summary is machine-generated.

Tolcapone, a Parkinson's disease drug, shows potential for Alzheimer's disease by binding to amyloid-beta and preventing toxic metal interactions. This suggests new therapeutic avenues for neurodegenerative disorders.

Keywords:
aggregationamyloid-betaantioxidantbinding constantneurodegenerationtolcapone

More Related Videos

Automated, Long-term Behavioral Assay for Cognitive Functions in Multiple Genetic Models of Alzheimer's Disease, Using IntelliCage
06:46

Automated, Long-term Behavioral Assay for Cognitive Functions in Multiple Genetic Models of Alzheimer's Disease, Using IntelliCage

Published on: August 4, 2018

12.9K
Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia
07:18

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia

Published on: November 9, 2018

9.0K

Related Experiment Videos

Last Updated: Mar 7, 2026

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
09:22

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

Published on: January 2, 2015

19.1K
Automated, Long-term Behavioral Assay for Cognitive Functions in Multiple Genetic Models of Alzheimer's Disease, Using IntelliCage
06:46

Automated, Long-term Behavioral Assay for Cognitive Functions in Multiple Genetic Models of Alzheimer's Disease, Using IntelliCage

Published on: August 4, 2018

12.9K
Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia
07:18

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia

Published on: November 9, 2018

9.0K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Biochemistry

Background:

  • Amyloid-beta (Aβ) aggregation and toxicity are key features of Alzheimer's disease (AD) and other neurodegenerative conditions.
  • Tolcapone, a drug for Parkinson's disease, has shown potential in modulating Aβ aggregation, but its molecular interactions are not well understood.

Purpose of the Study:

  • To investigate the binding interactions between tolcapone and both copper-free and copper-associated amyloid-beta species.
  • To explore the mechanisms by which tolcapone affects metal-amyloid-beta complexes.

Main Methods:

  • UV-vis spectroscopy
  • Circular dichroism
  • Mass spectrometry
  • Surface plasmon resonance
  • In vitro radical scavenging assays

Main Results:

  • Tolcapone directly binds to amyloid-beta monomers.
  • Tolcapone acts as a radical scavenger.
  • Tolcapone competes with amyloid-beta for copper ion binding.
  • Tolcapone can prevent metal coordination to Aβ and disrupt preformed Aβ-metal complexes.

Conclusions:

  • Tolcapone exhibits multifaceted protective effects against amyloid-beta aggregation and toxicity.
  • The drug's ability to interfere with metal-amyloid-beta interactions offers new therapeutic strategies for neurodegenerative diseases.
  • Tolcapone analogs may be developed for treating conditions like Alzheimer's disease and glaucoma.